X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (296) 296
Publication (32) 32
Conference Proceeding (25) 25
Book Review (14) 14
Book / eBook (2) 2
Newspaper Article (2) 2
Patent (2) 2
Streaming Audio (2) 2
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (168) 168
index medicus (164) 164
oncology (132) 132
female (118) 118
middle aged (97) 97
male (93) 93
adult (84) 84
aged (75) 75
cancer (67) 67
life sciences (62) 62
chemotherapy (45) 45
research (40) 40
santé publique et épidémiologie (36) 36
treatment outcome (36) 36
care and treatment (35) 35
french guiana (34) 34
aged, 80 and over (32) 32
[ sdv.spee ] life sciences [q-bio]/santé publique et épidémiologie (29) 29
retrospective studies (29) 29
risk factors (29) 29
mutation (28) 28
patients (28) 28
survival (28) 28
hiv (27) 27
infectious diseases (27) 27
prognosis (27) 27
antineoplastic combined chemotherapy protocols - therapeutic use (26) 26
clinical trials (25) 25
young adult (25) 25
disease-free survival (24) 24
medicine (23) 23
tumors (23) 23
health aspects (22) 22
metastasis (22) 22
mortality (22) 22
surgery (22) 22
colorectal cancer (21) 21
diagnosis (21) 21
survival analysis (21) 21
analysis (20) 20
epidemiology (20) 20
french guiana - epidemiology (20) 20
hematology, oncology and palliative medicine (20) 20
research article (20) 20
breast cancer (19) 19
carcinoma (19) 19
genetic predisposition to disease (19) 19
histoplasmosis (19) 19
breast neoplasms - genetics (18) 18
drug therapy (18) 18
france (18) 18
medicine & public health (18) 18
neoplasm staging (18) 18
therapy (18) 18
abridged index medicus (17) 17
aids (17) 17
antineoplastic agents - therapeutic use (17) 17
cancer therapies (17) 17
esophageal cancer (17) 17
heterozygote (17) 17
multivariate analysis (17) 17
antineoplastic agents - administration & dosage (16) 16
human immunodeficiency virus--hiv (16) 16
tropical medicine (16) 16
antineoplastic agents (15) 15
antineoplastic agents - adverse effects (15) 15
colorectal neoplasms - drug therapy (15) 15
fluorouracil (15) 15
gastrointestinal stromal tumors - drug therapy (15) 15
quality of life (15) 15
acquired immune deficiency syndrome--aids (14) 14
chemoradiotherapy (14) 14
disease (14) 14
disease progression (14) 14
fluorouracil - administration & dosage (14) 14
follow-up studies (14) 14
infections (14) 14
medical and health sciences (14) 14
medicin och hälsovetenskap (14) 14
public, environmental & occupational health (14) 14
skin and connective tissue diseases (14) 14
studies (14) 14
antimitotic agents (13) 13
cisplatin (13) 13
genotype (13) 13
human health and pathology (13) 13
incidence (13) 13
medical prognosis (13) 13
patient outcomes (13) 13
polymorphism, single nucleotide (13) 13
prevalence (13) 13
survival rate (13) 13
brca1 protein - genetics (12) 12
cohort studies (12) 12
colorectal neoplasms - pathology (12) 12
genetics (12) 12
imatinib mesylate (12) 12
kaplan-meier estimate (12) 12
medical research (12) 12
medicine and health sciences (12) 12
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 8, pp. 937 - 948
Summary Background Tumour mutational status is an important determinant of the response of metastatic colorectal cancer to targeted treatments. However, the... 
Hematology, Oncology and Palliative Medicine | KRAS MUTATIONS | 1ST-LINE TREATMENT | LEUCOVORIN | PLUS IRINOTECAN | ONCOLOGY | RANDOMIZED PHASE-III | INHIBITS GROWTH | ACQUIRED-RESISTANCE | FLUOROURACIL | PLACEBO PLUS | TUMOR-GROWTH | Predictive Value of Tests | Proto-Oncogene Proteins p21(ras) | Colorectal Neoplasms - genetics | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Clinical Trials, Phase III as Topic | Time Factors | DNA Mutational Analysis | Colorectal Neoplasms - drug therapy | Real-Time Polymerase Chain Reaction | Precision Medicine | Receptor, TIE-1 - blood | Phosphatidylinositol 3-Kinases - blood | Genetic Predisposition to Disease | Adenocarcinoma - blood | ras Proteins - blood | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Disease Progression | Phenotype | Class I Phosphatidylinositol 3-Kinases | Biomarkers, Tumor - genetics | ras Proteins - genetics | Patient Selection | DNA, Neoplasm - blood | Female | Adenocarcinoma - genetics | Retrospective Studies | Pyridines - therapeutic use | Colorectal Neoplasms - mortality | Colorectal Neoplasms - blood | Kaplan-Meier Estimate | Proportional Hazards Models | Phenylurea Compounds - therapeutic use | Proto-Oncogene Proteins B-raf - blood | Proto-Oncogene Proteins - genetics | Treatment Outcome | Randomized Controlled Trials as Topic | Biomarkers, Tumor - blood | Phosphatidylinositol 3-Kinases - genetics | Disease-Free Survival | Proto-Oncogene Proteins B-raf - genetics | Aged | DNA, Neoplasm - genetics | Colorectal Neoplasms - pathology | Proto-Oncogene Proteins - blood | Adenocarcinoma - mortality | Medical colleges | Medical research | Cancer patients | Prognosis | Liver | DNA | Colorectal cancer | Genetic research | Medicine, Experimental | Metastasis | Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 4, pp. 395 - 405
Journal Article
The Lancet Infectious Diseases, ISSN 1473-3099, 10/2018, Volume 18, Issue 10, pp. 1150 - 1159
Fungal infections remain a major contributor to the opportunistic infections that affect people living with HIV. Among them, histoplasmosis is considered... 
INFECTIOUS DISEASES | GUATEMALA | SERIOUS FUNGAL-INFECTIONS | Histoplasmosis | Models | Tuberculosis | Comparative analysis | HIV (Viruses) | Dilution | Acquired immune deficiency syndrome--AIDS | Human immunodeficiency virus--HIV | Mortality | Fatalities | Skin | Modelling | Infections | Skin tests | Incidence | Index Medicus | Life Sciences | Santé publique et épidémiologie
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 3, pp. 305 - 314
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2013, Volume 31, Issue 1, pp. 23 - 29
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 10, pp. 942 - 949
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2011, Volume 364, Issue 19, pp. 1817 - 1825
In this study, a four-drug combination chemotherapy regimen was associated with objective responses in more than 30% of patients and increased survival by more... 
PHASE-III TRIAL | 5-FLUOROURACIL | MEDICINE, GENERAL & INTERNAL | SOLID TUMORS | CLINICAL-TRIALS | IRINOTECAN | OXALIPLATIN | 1ST-LINE THERAPY | COMBINATION | CARCINOMA | COOPERATIVE-ONCOLOGY-GROUP | Leucovorin - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Pancreatic Neoplasms - drug therapy | Deoxycytidine - therapeutic use | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Neoplasm Metastasis - drug therapy | Adult | Camptothecin - administration & dosage | Deoxycytidine - adverse effects | Female | Pancreatic Neoplasms - mortality | Camptothecin - analogs & derivatives | Severity of Illness Index | Pancreatic Neoplasms - pathology | Proportional Hazards Models | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Antimetabolites, Antineoplastic - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antimetabolites, Antineoplastic - adverse effects | Survival Analysis | Quality of Life | Aged | Deoxycytidine - analogs & derivatives | Adenocarcinoma - mortality | Chemotherapy, Combination | Usage | Care and treatment | Gemcitabine | Pancreatic cancer | Leucovorin | Comparative analysis | Drug therapy | Fluorouracil | Clinical trials | Cytotoxicity | Pancreas | Patients | Index Medicus | Abridged Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 5, pp. 632 - 641
Journal Article